GRI (GRI Bio, Inc. Common Stock) Stock Analysis - Financials

GRI Bio, Inc. Common Stock (GRI) is a publicly traded Healthcare sector company. As of May 21, 2026, GRI trades at $2.23 with a market cap of $3.09M and a P/E ratio of -0.02. GRI moved -0.45% today. Year to date, GRI is -74.50%; over the trailing twelve months it is -94.58%. Its 52-week range spans $1.97 to $852.04. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces GRI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are GRI's key financials?

GRI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GRI recently traded at $2.23. Market cap is $3.09M. P/E ratio is -0.02. Revenue is $0.

GRI Key Metrics

Key financial metrics for GRI
MetricValue
Price$2.23
Market Cap$3.09M
P/E Ratio-0.02
EPS$-121.80
Dividend Yield0.00%
52-Week High$852.04
52-Week Low$1.97
Volume50
Avg Volume0
Revenue (TTM)$0
Net Income$-11.96M
Gross Margin0.00%

GRI Annual Financials

YearRevenueNet IncomeEPS
2025$0$-11.96M$-121.80
2024$0$-8.21M$-55.21
2023$0$-13.04M$-28.25

Latest GRI News

GRI Analyst Consensus

2 analysts cover GRI: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.

Common questions about GRI

What are GRI's key financials?
GRI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GRI recently traded at $2.23. Market cap is $3.09M. P/E ratio is -0.02. Revenue is $0.
Is GRI research on Rallies investment advice?
No. Rallies provides research, data, and educational context for GRI. It does not provide personalized investment advice.
GRI

GRI